Clinical Trials Logo

Marijuana Abuse clinical trials

View clinical trials related to Marijuana Abuse.

Filter by:

NCT ID: NCT04374773 Active, not recruiting - Pregnancy Related Clinical Trials

Effects of Pregnancy-associated Hormones on THC Metabolism in Women

PrECEPT
Start date: October 19, 2020
Phase: Phase 4
Study type: Interventional

Cannabis use is prevalent among pregnant women, but the effects of use on both the developing fetus and pregnant woman are unknown. Importantly, drug exposure could be influenced by the impact of pregnancy-associated hormones on the metabolism of tetrahydrocannabinol (THC), the main psychoactive component of cannabis. The goal of this study is to determine whether cortisol and estradiol - hormones that rise dramatically during pregnancy - increase the clearance of dronabinol (THC) in reproductive age women to simulate the pregnant state. The collected data will then be used to predict the time course and magnitude of changes in THC metabolism in pregnant women, particularly with gradually increasing estradiol and cortisol concentrations that evolve over the course of pregnancy. The overall objective of this study is to better understand the effects of THC use during pregnancy on the health of the pregnant woman and developing fetus.

NCT ID: NCT03581058 Active, not recruiting - Cannabis Use Clinical Trials

Neural Correlates of Driving and Cannabis

Start date: August 8, 2018
Phase: Phase 1
Study type: Interventional

Driving is a set of complex tasks and requires use of multiple cognitive domains, including attention, planning, and memory. In laboratory studies, the main psychoactive component in cannabis, delta-9-tetrahydrocannabinol (THC), was shown to impair short-term memory, attention, reaction time, tracking, and coordination, resulting, for instance, in significantly more deviations from the lane and increased break latency. Surveys and epidemiological studies suggest that cannabis consumption is associated with increased risks of collision. The current study aims to evaluate individual driving behavior and performance on various neurocognitive tests and their correlated neural networks while under the influence of cannabis and while sober. The investigators will use the STISIM driving simulator, which is fully MRI compatible, to study brain activation, while participants are performing various driving maneuvers. The goals of the study are: 1. identify driving performance and patterns in brain activation associated with cannabis exposure and compare them to brain patterns of the same participants while sober; 2. compare participant's performance on cognitive tasks while under the influence of cannabis and sober; 3. look for correlations between concentration of cannabinoids in the participants' blood and their driving performance and performance on cognitive tasks; 4. correlate demographic variables and personal history (e.g. tolerance to drug) with performance and brain activation while driving under the influence of cannabis.

NCT ID: NCT03560934 Active, not recruiting - Sleep Clinical Trials

Tetrahydrocannabinol (THC) and Sleep

Start date: September 1, 2018
Phase: Early Phase 1
Study type: Interventional

The investigators will test the effects of 10-60mg dronabinol (oral THC) on sleep in non-frequent and frequent cannabis users.

NCT ID: NCT03379857 Active, not recruiting - Stroke Clinical Trials

Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke

CANNASTROKE
Start date: January 11, 2018
Phase: N/A
Study type: Interventional

Incidence of strokes has increased these last 20 years in young population. This rise could be linked to alcohol, tobacco or drug use like cannabis. Cannabis has previously been descripted as a potential factor of reversible vasoconstriction. The main objective is to show that an exhaustive assessment of a stroke facing a young person frequently lead to a diagnostic of reversible vasoconstriction due to cannabis use. Evaluation will focus on prevalence of strokes secondary to a reversible vasoconstriction attributable to cannabis in young subjects. There's a real public healthcare interest in terms of primary and secondary prevention to evaluate the role of cannabis as a risk factor of stroke in young population.

NCT ID: NCT02083874 Active, not recruiting - Clinical trials for Cannabis Use Disorder

Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study

Start date: March 2014
Phase: Phase 2
Study type: Interventional

Single subject repeated measures design of an open label administration of Cannabidiol (CBD) to 5 participants withdrawing from cannabis use in an inpatient setting. 300mg of CBD will be administered once on day 1, twice on days 2-5 and once on day 6. Participants will be discharged on day 7. CBD will be administered orally in capsules.

NCT ID: NCT01827332 Active, not recruiting - Clinical trials for Marijuana Dependence

Effect of Oxytocin on Craving and Therapy Response

Start date: March 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the impact of a medication called oxytocin on craving, marijuana use, and therapy response in people who frequently use marijuana. .

NCT ID: NCT01574183 Active, not recruiting - Clinical trials for Marijuana Dependence

Vilazodone Treatment for Marijuana Dependence

Start date: August 2012
Phase: Phase 2
Study type: Interventional

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.

NCT ID: NCT01539525 Active, not recruiting - Clinical trials for Tobacco Use Disorder

Screening to Augment Referral to Treatment- Project START

ProjectSTART
Start date: September 2010
Phase: Phase 2
Study type: Interventional

The investigators propose to use obstetric-gynecological clinics to conduct a randomized clinical trial that would compare two SBIRTS (Screening, Brief Intervention, Referral and Treatment), delivered either by a trained nurse or by computer, to usual care (a control condition). As part of this trial, the investigators will include outcomes that allow us to assess the cost effectiveness of these three conditions.

NCT ID: NCT00875836 Active, not recruiting - Clinical trials for Marijuana Dependence

Buspirone Treatment for Marijuana Dependence

Start date: September 2009
Phase: Phase 4
Study type: Interventional

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management (CM) intervention and motivational enhancement therapy (MET) will be incorporated to encourage study engagement and retention. It is hypothesized that buspirone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.

NCT ID: NCT00484367 Active, not recruiting - Alcohol Dependence Clinical Trials

A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers

Start date: July 1999
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of two psychosocially-based, manual-driven, behavioral modalities. One of these is a standardized version of the established modality of Adolescent Group Therapy (AGT), which includes both psychoeducational and therapeutic components. The other is a state-of-the-art family therapy approach, Transitional Family Therapy (TFT), which integrates management of the current problem with exploration of multigenerational issues. Both approaches have been developed to expressly target adolescent alcohol problems.